In vivo RNA interference-mediated ablation of MDR1 P-glycoprotein

Clinical Cancer Research

Volumn 11, Issue 12, 2005, Pages 4487-4494

  Pichler, Andrea ^a   Zelcer, Noam ^c,d   Prior, Julie L ^a   Kuil, Annemieke J ^c   Piwnica Worms, David ^a,b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NETHERLANDS CANCER INSTITUTE   (Netherlands)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COELENTERAZINE; DOXORUBICIN; ENHANCED GREEN FLUORESCENT PROTEIN; FLUORESCENT DYE; GLYCOPROTEIN P; GLYCOPROTEIN P ENHANCED GREEN FLUORESCENT FUSION PROTEIN; HYBRID PROTEIN; LUCIFERASE; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 1 FIREFLY LUCIFERASE FUSION PROTEIN; PACLITAXEL; SHORT HAIRPIN RNA; TECHNETIUM 99M; UNCLASSIFIED DRUG; VINCRISTINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOLUMINESCENCE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; DRUG EFFICACY; DRUG SENSITIVITY; EMBRYO; FLUORESCENCE MICROSCOPY; GENE CONSTRUCT; GENE EXPRESSION REGULATION; GENE FUSION; GENE OVEREXPRESSION; GENETIC TRANSDUCTION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HYDRODYNAMICS; MALE; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TRANSPORT; REPORTER GENE; RNA INTERFERENCE; SOMATIC GENE THERAPY; WESTERN BLOTTING;

ANIMALS; BIOLOGICAL TRANSPORT; CELL LINE; CELL LINE, TUMOR; CELL SURVIVAL; DOWN-REGULATION; GENETIC VECTORS; GREEN FLUORESCENT PROTEINS; HUMANS; IMMUNOBLOTTING; LUCIFERASES; LUMINESCENT MEASUREMENTS; MALE; MICE; MICE, NUDE; P-GLYCOPROTEIN; RECOMBINANT FUSION PROTEINS; RNA INTERFERENCE; RNA, SMALL INTERFERING; TRANSFECTION; VINCRISTINE;

EID: 20444482419     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-0038     Document Type: Article

References (42)

1. Ling V. Multidrug resistance and P-glycoprotein expression. Ann N Y Acad Sci 1987;507:7-8.
2. Bradley G, Ling V. P-glycoprotein, multidrug resistance and tumor progression. Cancer Metastasis Rev 1994;13:223-33.
3. Borst P, Elferink RO. Mammalian ABC transporters in health and disease. Annu Rev Biochem 2002;71:537-92.
4. Dean M, Rzhetsky A, Allikmets R. The human ATP-binding cassette (ABC) transporter superfamily. Genome Res 2001;11:1156-66.
5. Gottesman M, Fojo T, Bates S. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2002;2:48-58.
6. Bates SF, Chen C, Robey R, Kang M, Figg WD, Fojo T. Reversal of multidrug resistance: lessons from clinical oncology. Novartis Found Symp 2002;243:83-96; discussion 96-102, 180-5.
7. Caplen NJ, Mousses S. Short interfering RNA (siRNA)-mediated RNA interference (RNAi) in human cells. Ann N Y Acad Sci 2003;1002:56-62.
8. Agrawal N, Dasaradhi PV, Mohmmed A, Malhotra P, Bhatnagar RK, Mukherjee SK. RNA interference: biology, mechanism, and applications. Microbiol Mol Biol Rev 2003;67:657-85.
9. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001;411:494-8.
10. Bernstein E, Caudy AA, Hammond SM, Hannon GJ. Role for a bidentate ribonuclease in the initiation step of RNA interference. Nature 2001;409:363-6.
11. Stevenson M. Therapeutic potential of RNA interference. N Engl J Med 2004;351:1772-7.
12. Brummelkamp TR, Bernards R, Agami R. A system for stable expression of short interfering RNAs in mammalian cells. Science 2002;296:550-3.
13. Reid G, Wielinga P, Zelcer N, et al. The human multidrug resistance protein MRP4 functions as a prostaglandin efflux transporter and is inhibited by non-steroidal antiinflammatory drugs. Proc Natl Acad Sci U S A 2003;100:9244-9.
14. Rao V, Dahlheimer J, Bardgett M, et al. Choroid plexus epithelial expression of MDR1 P-glycoprotein and multidrug resistance-associated protein contribute to the blood-cerebrospinal fluid drug-permeability barrier. Proc Natl Acad Sci U S A 1999;96:3900-5.
15. Piwnica-Worms D, Rao V, Kronauge J, Croop J. Characterization of multidrug-resistance P-glycoprotein transport function with an organotechnetium cation. Biochemistry 1995;34:12210-20.
16. Pichler A, Prior J, Piwnica-Worms D. Imaging reversal of multidrug resistance in living mice with bioluminescence: MDR1 P-glycoprotein transports coelenterazine. Proc Natl Acad Sci U S A 2004;101:1702-7.
17. Luker G, Bardill J, Prior J, Pica C, Piwnica-Worms D, Leib D. Noninvasive bioluminescence imaging of herpes simplex virus type 1 infection and therapy in living mice. J Virol 2002;76:12149-61.
18. Liu F, Song Y, Liu D. Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA. GeneTher 1999;6:1258-66.
19. Glantz SA. Primer of biostatistics. 2nd ed. New York: Mcgraw-Hill, Inc.; 1987. p. 379.
20. Kool M, de Haas M, Scheffer GL, et al. Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. Cancer Res 1997;57:3537-47.
21. Piwnica-Worms D, Chiu M, Budding M, Kronauge J, Kramer R, Croop J. Functional imaging of multidrug-resistant P-glycoprotein with an organotechnetium complex. Cancer Res 1993;53:977-84.
22. Mistry P, Stewart A, Dangerfield W, et al. In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576. Cancer Res 2001;61:749-58.
23. Dantzig A, Shepard R, Cao J, et al. Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979. Cancer Res 1996;56:4171-9.
24. Kobayashi H, Dorai T, Holland JF, Ohnuma T. Reversal of drug sensitivity in multidrug-resistant tumor cells by an MDR1 (PGY1) ribozyme. Cancer Res 1994;54:1271-5.
25. Holm PS, Scanlon KJ, Dietel M. Reversion of multidrug resistance in the P-glycoprotein-positive human pancreatic cell line (EPP85-181RDB) by introduction of a hammerhead ribozyme. Br J Cancer 1994;70:239-43.
26. Liu C, Qureshi IA, Ding X, et al. Modulation of multidrug resistance gene (mdr-1) with antisense oligodeoxynucleotides. Clin Sci (Lond) 1996;91:93-8.
27. Stuart DD, Kao GY, Allen TM. A novel, long-circulating, and functional liposomal formulation of antisense oligodeoxynucleotides targeted against MDR1. Cancer GeneTher 2000;7:466-75.
28. Nieth C, Priebsch A, Stege A, Lage H. Modulation of the classical multidrug resistance (MDR) phenotype by RNA interference (RNAi). FEBS Lett 2003;545:144-50.
29. Wu H, Hait WN, Yang JM. Small interfering RNA-induced suppression of MDR1 (P-glycoprotein) restores sensitivity to multidrug-resistant cancer cells. Cancer Res 2003;63:1515-9.
30. Yague E, Higgins CF, Raguz S. Complete reversal of multidrug resistance by stable expression of small interfering RNAs targeting MDR1. GeneTher 2004;11:1170-4.
31. Elbashir SM, Harborth J, Weber K, Tuschl T. Analysis of gene function in somatic mammalian cells using small interfering RNAs. Methods 2002;26:199-213.
32. Reynolds A, Leake D, Boese Q, Scaringe S, Marshall WS, Khvorova A. Rational siRNA design for RNA interference. Nat Biotechnol 2004;22:326-30.
33. Stege A, Priebsch A, Nieth C, Lage H. Stable and complete overcoming of MDR1/P-glycoprotein-mediated multidrug resistance in human gastric carcinoma cells by RNA interference. Cancer Gene Ther 2004;11:699-706.
34. Ciarmiello A, Del Vecchio S, Silvestro P, et al. Tumor clearance of technetium-99m-Sestamibi as a predictor of response to neoadjuvant chemotherapy for locally advanced breast cancer. J Clin Oncol 1998;16:1677-83.
35. Sharma V, Piwnica-Worms D. Monitoring multidrug resistance P-glycoprotein drug transport activity with single-photon emission computed tomography and positron emission tomography radiopharmaceuticals. Top Curr Chem 2005;252:155-78.
36. Sukan A, Yapar Z, B SA, et al. 99mTc tetrofosmin scintigraphy in acute leukaemia: the relationship between marrow uptake of tetrofosmin and P-glycoprotein and chemotherapy response. Nucl Med Commun 2004; 25:777-85.
37. Chen C, Meadows B, Regis J, et al. Detection of in vivo P-glycoprotein inhibition by PSC 833 using Tc-99m-Sestamibi. Clin Cancer Res 1997;3:545-52.
38. 99mTc-Tetrofosim chest imaging. J Nucl Med 2001;42:17-20.
39. Shankar P, Manjunath N, Lieberman J. The prospect of silencing disease using RNA interference. J Am Med Assoc 2005;293:1367-73.
40. Begley DJ. ABC transporters and the blood-brain barrier. Curr Pharm Des 2004;10:1295-312.
41. Schinkel A, Smit J, van Tellingen O, et al. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 1994; 77:491-502.
42. Holm PS, Lage H, Bergmann S, et al. Multidrug-resistant cancer cells facilitate E1-independent adenoviral replication: impact for cancer gene therapy. Cancer Res 2004;64:322-8.